Atara Biotherapeutics, Inc. is a privately-held drug development company with a focus on innovative therapies for patients with debilitating diseases. The research of Atara and its family of companies is based on groundbreaking discoveries regarding the ability of activin, myostatin and other biological targets to change the course of disease progression. Atara has three novel biologics in development, including PINTA 745 (Phase 2) for protein energy wasting in end-stage renal disease, STM 434 (IND-ready) for ovarian cancer and other solid tumors, and NINA 842 (pre-clinical) for cancer-related cachexia. Atara and its family of companies were launched in 2012 by a proven team of drug developers, Amgen, and Kleiner Perkins Caufield & Byers.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 12/17/13 | $38,500,000 | Series B |
Alexandria Real Estate Equities Amgen Business Development Celgene Corporation DAG Ventures Domain Associates EcoR1 Capital | undisclosed |
| 01/10/14 | $13,500,000 | Series B-1 |
Amgen Business Development Celgene Corporation DAG Ventures Domain Associates EcoR1 Capital The Baupost Group | undisclosed |
